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Abstract
Background: With the paucity of new drugs and HIV co-infection, vaccination remains an unmet research priority to combat
visceral leishmaniasis (VL) requiring strong cellular immunity. Protein vaccination often suffers from low immunogenicity
and poor generation of memory T cells for long-lasting protection. Cysteine proteases (CPs) are immunogenic proteins and
key mediators of cellular functions in Leishmania. Here, we evaluated the vaccine efficacies of CPs against VL, using cationic
liposomes with Toll like receptor agonists for stimulating host immunity against L. donovani in a hamster model.
Methodology/Principal Findings: Recombinant CPs type I (cpb), II (cpa) and III (cpc) of L. donovani were tested singly and in
combination as a triple antigen cocktail for antileishmanial vaccination in hamsters. We found the antigens to be highly
immunoreactive and persistent anti-CPA, anti-CPB and anti-CPC antibodies were detected in VL patients even after cure.
The liposome-entrapped CPs with monophosphoryl lipid A-Trehalose dicorynomycolate (MPL-TDM) induced significantly
high nitric oxide (up to 4 fold higher than controls) mediated antileishmanial activity in vitro, and resulted in strong in vivo
protection. Among the three CPs, CPC emerged as the most potent vaccine candidate in combating the disease.
Interestingly, a synergistic increase in protection was observed with liposomal CPA, CPB and CPC antigenic cocktail which
reduced the organ parasite burden by 1013–1016 folds, and increased the disease-free survival of .80% animals at least up
to 6 months post infection. Robust secretion of IFN-c and IL-12, along with concomitant downregulation of Th2 cytokines,
was observed in cocktail vaccinates, even after 3 months post infection.
Conclusion/Significance: The present study is the first report of a comparative efficacy of leishmanial CPs and their cocktail
using liposomal formulation with MPL-TDM against L. donovani. The level of protection attained has not been reported for
any other subcutaneous single or polyprotein vaccination against VL.
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Introduction
Visceral leishmaniasis (VL) caused by Leishmania donovani is a
fatal disease with an estimated 360,000 new cases all over the
world with almost 10% annual case fatality in the Indian
subcontinent alone [1]. It is a neglected tropical disease inevitably
associated with poverty and immunosuppression. High toxicity of
available drugs (amphotericin B, miltefosine and paromomycin),
HIV co-infection, and resistant parasites pose a global threat
against leishmaniases. Despite recent advances in pharmaceutics
and molecular immunology, there is no licensed vaccine available
against the disease till date [2]. Encapsulation of antigens within
nanocarriers promises stable and customized vaccine delivery to
related immune cells against various intracellular pathogens
including Leishmania. Although incompletely understood, the
lack of clinical efficacy for peptide-based vaccines may be related
to several factors such as poor immunogenicity of the subunit
antigens, inappropriate functional polarity of T cells and
Leishmania induced immunosuppression [2,3]. Thus, there
remains considerable scope for improvement of antileishmanial
vaccine design to maximize the chances of clinical benefit.
Outcome of prophylactic vaccination largely depends on the
choice of right immunopotentiating adjuvants and/or delivery
systems coupled to right antigen(s). Cationic liposomes protect the
labile antigens from lysosomal degradation and take the advantage
of electrostatic interactions with the cells’ negative charge which
makes them a natural target for antigen presenting cells (APCs),
crucial for immune stimulation [4,5]. Monophosphoryl lipid A
(MPLA) is a Toll-like receptor 4 (TLR4) agonist with more than
100,000 human doses safely administered as a part of licensed
hepatitis B and Human papillomavirus vaccines [6]. Mycobacte-
rial glycolipid trehalose-6,69-dimycolate (TDM; cord factor) is a
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potent immunostimulant known for its macrophage activation
properties and induction of proinflammatory cytokines, and anti-
tumor activity [7]. Recently, TDM has been shown to act via
macrophage receptor with collagenous structure (MARCO),
TLR2, CD14 and also macrophage-inducible C-type lectin
(Mincle) receptors to exert its immunomodifying effects [8,9].
When used together, both the adjuvants i.e. MPL and TDM non-
specifically activate the immune system, allowing a better response
to the associated immunogen [10]. Recently, we have developed a
cationic liposome and MPL-TDM (monophosphoryl lipid-treha-
lose dicorynomycolate) delivery platform that is suitable for
subcutaneous delivery of leishmanial antigens in mice model [11].
Compared to an array of antigens that have been tested, very
few are sufficiently promising to be carried out to Phase I clinical
trials or advanced preclinical work against VL [12]. Lysosomal
cysteine proteases (CP) of Leishmania, including cysteine proteases
type I (CPB), II (CPA) and III (CPC), are conserved and
functionally important proteolytic enzymes regulating cell cycle
and host-parasite interactions that have been found to be
immunogenic in mice. Further, CPs are established virulence
factors involved in parasitic survival, autophagy and metacyclo-
genesis essential for onset of the disease and are being increasingly
exploited as serodiagnostic markers, drug targets and vaccine
candidates against Leishmania [13,14]. Protein and DNA vaccine
attempts using CPA, CPB and CPC in different adjuvants have
been reported against L. major [15,16] and L. infantum [17] in
mice and canine models [18]. However, these research efforts have
been largely restricted to cutaneous and zoonotic VL with variable
success rate but have never been investigated against L. donovani,
the causative agent of kala-azar. Although mouse serves as a good
animal model for dissecting the protective immune responses with
the available immunological reagents, murine infection is usually
self-curing and differs from human VL. In contrast, hamsters
closely mimic clinical symptoms of human VL characterized by
severe immunosuppression (Th2 response) and develop progres-
sive fatal infection when challenged with L. donovani. Higher
innate susceptibility of this model compared to mice makes them a
better choice for initial vaccine trial against VL to ensure its
success in human [19]. Hence we selected Syrian golden hamsters
to assess the protective potential of leishmanial CPs. Our aim in
this study was therefore towards a comparative evaluation of
prophylactic potential of CPA, CPB and CPC, individually, as well
as a multi-antigen cocktail vaccine, maximizing the exposed
antigenic epitopes to protect against VL. Evidence is presented
here for the first time on the efficacy of highly potent liposomal
formulations of recombinant CPA, CPB and CPC along with
MPL-TDM adjuvant, in a hamster model against L. donovani,
with an aim towards its further development for human
vaccination.
Materials and Methods
Ethics statement
The present study was approved by the Ethical Committee on
Human Subjects at the Indian Institute of Chemical Biology and
Ethical Committee, Calcutta School of Tropical Medicine,
Kolkata. Written informed consent was obtained from each
patient and healthy donors enrolled in the study and the patient/
parent was informed that he/she was free to voluntarily withdraw
from the study at any time. Written consent was obtained from
parent or guardian in case of minors. The physicians explained the
nature of the investigation and the risks involved to each patient
(or parent or guardian in case of minors), prior to recruitment. A
copy of the patient consent form was submitted to the Ethical
Committee.
The animal experiments were approved by the Animal Ethical
Committee (147/1999/CPSCEA) of the institute, according to the
National Regulatory Guidelines issued by the Committee for the
Purpose of Control and Supervision on Experimental Animals
(CPCSEA), under the Division of Animal Welfare, Ministry of
Environment and Forest, Government of India.
Animals and parasites
Studies were performed with 4–6 weeks old Syrian golden
hamsters (Mesocricetus auratus) reared in pathogen-free animal
care facility of the Indian Institute of Chemical Biology. A strain of
L. donovani (MHOM/IN/83/AG83) originally isolated from an
Indian kala-azar patient was maintained by serial passage in
Syrian golden hamsters as described earlier [20]. Parasites from
stationary-phase culture were sub-cultured to maintain an average
density of 26106 cells/ml.
Cloning, expression and purification of L. donovani
cysteine proteases a, b and c
Plasmids containing full-length cpa (GenBank accession number
KF018070), cpb (GenBank accession number KC609324) and cpc
(GenBank accession number JX968801.1) from L. donovani
(pET28a-cpa, pET28a-cpb and pET28a-cpc) were cloned, ex-
pressed and purified from inclusion bodies using sarkosyl (Sigma-
aldrich, St. Louis, MO) [21]. Genomic DNA isolated from L.
donovani promastigotes was subjected to polymerase chain
reaction (PCR) with sets of gene specific primers corresponding
to cpa, cpb and cpc genes based on Leishmania major and
Leishmania infantum gene sequences (Table S1, supporting
information). PCR conditions for rCPA and rCPB were one cycle
of 5 min at 94uC, 35 cycles of 1 min at 94uC, 1 min at 59uC, and
1 min 10 s at 72uC, followed by a final cycle of 7 min at 72uC.
PCR conditions for rCPC were one cycle of 5 min at 94uC, 35
cycles of 1 min at 94uC, 1 min 20 s at 58uC, and 1 min 10 s at
72uC, followed by a final cycle of 7 min at 72uC. The PCR
Author Summary
Conventional chemotherapy of visceral leishmaniasis (VL)
typically relies on pentavalent antimonials that suffer from
extensive drug resistance in India. Development of
preventive vaccination is undoubtedly a better alternative
to completely eradicate the disease. With this in mind, we
chose to target parasite cysteine proteases (CPs), with
immense biological importance, as potential vaccine
candidates against Leishmania donovani. Here, we describe
the superior efficacy of an antigenic cocktail of type I, II
and III CPs entrapped in cationic liposomes with Toll like
receptor (TLR) agonists: monophosphoryl lipid A- Treha-
lose dicorynomycolate (MPL-TDM), against L. donovani in a
hamster model. The three CPs acted synergistically in the
cocktail to induce almost complete protection against
Leishmania. The protection is chiefly mediated through
upregulation of protective cytokines like interferon-gam-
ma (IFN-c), interleukin-12 (IL-12), IL-2, and tumour necrosis
factor (TNF-a), with concomitant down-regulation of
disease promoting cytokines, like transforming growth
factor–beta (TGF-b), IL-10 and IL-4. The antigens were also
compared singly for their protective potential. Interesting-
ly, type III (CPC) CP emerged as the most potent antigenic
component of the cocktail inducing better protection than
type I and II. Hence, the cysteine proteases of Leishmania
form an attractive group of vaccine candidates for future
studies in human VL.
Cocktail Vaccination against Leishmania donovani
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amplified fragments were separately cloned into NdeI/BamHI site
of bacterial expression vector pET28a (Novagen, Madison, USA).
All the restriction enzymes were from Roche Diagnostics,
Mannheim, Germany. Screening for recombinant clones was
performed by growing randomly selected colonies overnight at
37uC in 5 ml of Luria-Bertani (LB) broth (with 35 mg/ml
kanamycin). Plasmid DNA were extracted from bacterial cell
pellets using the QIAprep Spin Miniprep Kit (Qiagen, Valencia,
USA), following the manufacturer’s instructions. For clone
confirmation, approximately 1 mg plasmid DNA from an individ-
ual miniprep was double digested with the appropriate restriction
enzymes (NdeI and HindIII) and the digest loaded onto a 1%
agarose gel, in parallel with the molecular weight marker: 1 kb
DNA ladder (Fermentas, USA). Positive clones were selected on
the basis of the size of the insert and confirmed by DNA
sequencing (ABI Prism, Model 377; Applied Biosystems). Esche-
richia coli BL21 (DE3) transformed with each of pET28a-cpa,
pET28a-cpb and pET28a-cpc constructs were grown in 500 ml of
culture medium at 37uC until logarithmic phase OD600 reached
0.6. Protein production was induced by adding isopropyl b-d-
thiogalactoside (IPTG) to a final concentration of 0.5 mM, and
incubating for an additional 4 h at 30uC. The culture was then
harvested by centrifugation at 6,0006g, for 6 min, at 4uC, and the
cell pellet was resuspended in 6 ml of resuspension buffer [25 mM
Tris-HCl, 500 mM NaCl, and 1 mg/ml of Lysozyme (Roche),
pH 8.0]. The cell lysate was sonicated on ice for 5 min with 1 min
pulse and 1 min interval between pulses using an ultrasonicator
(Misonix, Farmingdale, NY, USA). The pellet containing inclusion
bodies was solubilised with solublization buffer [50 mM CAPS {3-
(Cyclohexylamino)-1-propanesulfonic acid} buffer (pH 11.0),
300 mM NaCl, and 0.5% sarkosyl], kept at room temperature
for 30 min and finally centrifuged at 12,0006g for 30 min at 4uC.
The supernatant containing solubilised proteins were loaded
separately onto Ni2+-nitrilotriacetic acid-agarose (Ni-NTA) col-
umn (Qiagen) and purified under denaturing conditions [16]. The
Ni-NTA column was pre equilibriated with equilibriation buffer
[50 mM CAPS buffer (pH 11.0), 150 mM NaCl, 0.5% sarkosyl
and 10 mM imidazole]. The column was washed with wash buffer
[50 mM CAPS buffer (pH 11.0), 150 mM NaCl, 0.5% sarkosyl
and 20 mM imidazole] and eluted with elution buffer [50 mM
CAPS buffer (pH 11.0), 150 mM NaCl, 0.5% sarkosyl and
300 mM imidazole]. Bacterial endotoxins were largely removed
by three consecutive washing of the protein bound Ni-NTA
agarose beads with wash buffer containing 0.5% and 0.1% (v/v)
Triton X-114 (Sigma-Aldrich) [22]. This was followed by washing
the beads without the detergent (in 20 volumes of wash buffer
without Triton X-114) prior to elution. The endotoxin level in
each of the recombinant proteins was determined using the
chromogenic Limulus Amebocyte Lysate (LAL) assay kit (QCL-
1000; Lonza) according to the manufacturer’s recommendations.
This step was repeated as required to maintain the endotoxin
content of the purified recombinant proteins as ,0.2 endotoxin
units/mg. To refold, the purified materials were diluted 2 fold in
dilution buffer containing 50 mM CAPS buffer (pH 11.0),
150 mM NaCl and 300 mM imidazole, and then dialyzed against
25 mM Tris-HCl, 250 mM NaCl, pH 8.0 and finally in 0.02 M
PBS for 6 h at 4uC. Protein concentrations were determined using
Lowry’s method [23]. Purity and homogeneity of the purified
proteins were checked on10% sodium dodecyl sulfate (SDS)-
PAGE, and the gel was subsequently stained with Coomassie
Brilliant Blue R-250 (Bio-Rad Laboratories).
ClustalW DNA alignment was performed using the ClustalW
program of the European Bioinformatics Institute (http://www.
genome.jp/tools-bin/clustalw) and multiple alignment was used to
view the ClustalW alignment [24]. Cysteine protease gene
sequences of different Leishmania species were derived from the
GenBank.
Detection of anti-CPA, anti-CPB and anti-CPC antibodies
in VL patients
Blood plasma samples were obtained from five patients
confirmed with active VL, admitted between 2009 and 2012 to
the School of Tropical Medicine (Kolkata, India) mainly from
endemic regions of Bihar and West Bengal. Five recovered cases of
liposomal amphotericin B -treated patients and five normal
individuals negative for the recombinant K39 strip test from a
non-endemic area were included as cured and healthy controls
respectively. HIV-positive individuals with VL and pregnant
women were excluded from study. Heparinized, longitudinal
blood samples were collected from the patients (both with active
VL and cured) as well as healthy individuals from which about
1 ml of plasma was used for the study. Plasma was obtained from
the upper layer of the gradient following centrifugation and stored
at 220uC until use. Purified CPs (rCPA, rCPB and rCPC) (5 mg)
were subjected to 10% SDS-polyacrylamide gel electrophoresis
[25], transferred (Mini-Protean II, Bio-Rad) to nitrocellulose
membrane at 85 V for 1 h and incubated with human plasma
(1:1000) from patients with active VL, cured and healthy
individuals. The membranes were washed and probed with
horseradish peroxidase (HRP)-conjugated goat anti-human IgG
(1:4000) (Southern Biotech) as secondary antibody. The present
study was approved by the Ethical Committee on Human Subjects
at the Indian Institute of Chemical Biology.
Preparation of DSPC-bearing cationic liposomes and
entrapment of recombinant proteins
Distearoyl phosphatidylcholine (DSPC), cholesterol (Sigma-
aldrich) and stearylamine (Fluka, Buchs, Switzerland) at a molar
ratio of 7:2:2 were dissolved in chloroform followed by evaporating
the organic solvents to form a thin film as described earlier [26].
Empty and antigen entrapped liposomes were prepared by
dispersion of lipid film in either 1 ml of 0.02 M phosphate
buffered saline (PBS) alone or containing 500 mg/ml of recombi-
nant CPA (rCPA), CPB (rCPB) or CPC (rCPC). The mixture was
then vortexed and the suspension was sonicated for 30 s by an
ultrasound probe sonicator (Misonix, New York, USA) thrice with
1 min gap in between at 4uC. It was then kept on ice for 2 h to
stabilize the formed liposomes. Vesicles with entrapped antigen
were separated from excess free antigens by three successive
washings in PBS with ultracentrifugation at 105,0006g for 1 h at
4uC.The protein entrapped in liposome was estimated using BSA
as the standard, in presence of 0.8% SDS and appropriate blanks
[23]. Protein integrity after liposomal encapsulation was also
evaluated by 10% SDS-PAGE followed by Coomassie staining.
For fluorescent liposomes, the lipid film was made with DSPC,
cholesterol and stearylamine at a molar ratio of 7:2:2 along with
0.1 mg/ml of rhodamine 123 (Rh123) (Sigma Life Sciences) as a
lipophilic marker. The dry lipid film was dispersed in 0.02 M PBS
and the excess free dye was separated from labeled liposomes by
three successive washings as described above.
Characterization of liposomes by atomic forced
microscopy
For atomic forced microscopy (AFM) imaging of liposomal
samples, 10 ml of the samples were deposited onto freshly cleaved
muscovite Ruby mica sheets (ASTM V1 Grade Ruby Mica
from MICAFAB) for 15–20 minutes. Mica sheets are basically
Cocktail Vaccination against Leishmania donovani
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negatively charged so samples bind strongly on the mica surface.
After 15 min, the samples were dried by using a vacuum dryer.
Sometimes the samples were gently washed with 0.5 ml Milli-Q
water to remove molecules that were not firmly attached to the
mica and the samples were dried as mentioned above. Acoustic
alternative current mode AFM was performed using a Pico plus
5500 ILM AFM (Agilent Technologies, USA) with a piezoscanner
maximum range of 9 mm. Micro fabricated silicon cantilevers of
225 mm in length with a nominal spring force constant of 21–98
N/m were used from Nano sensors, USA. Cantilever oscillation
frequency at 150–300 kHz was tuned into resonance frequency.
The images (512 by 512 pixels) were captured with a scan size
between 0.5 and 2 mm at a scan speed rate of 0.5lines/S.
Images were flattened using Pico view1.4 version software
(Agilent Technologies). Image processing and analyzation was
done through Pico Image Advanced version software (Agilent
Technologies).
Flowcytometry
The mechanism of cellular uptake of liposomes was quantified
by fluorescence activated cell sorting (FACS) using various
biochemical inhibitors. Macrophages collected by peritoneal
lavage of healthy, adult Syrian golden hamsters were incubated
overnight in a 24-well flat bottom plate at a density of 16106 cells/
well in RPMI 1640/10% fetal bovine serum (FBS). Cells were
incubated in serum free RPMI 1640 with various biochemical
inhibitors (all from Sigma-Aldrich): 500 mM amiloride, 5 mg/ml
chlorpromazine, 50 mg/ml cytochalasin D for 30 min and 10 mM
colchicine for 2 h to block macropinocytosis, non-clathrin, non-
caveolae dependent endocytosis, actin and microtubules mediated
endocytosis, respectively [27–29]. Cells were subsequently treated
with rhodamine 123 (Rh123)-labelled cationic liposomes (final
concentration 0.2 mg lipid/ml with respect to DSPC) for 1 h in
the presence of the inhibitors. Cells incubated with labelled
liposomes without prior treatment with inhibitors served as
positive controls. Cells were detached using trypsin/EDTA,
washed thrice with ice-cold 0.02 M PBS containing 0.5% FBS,
and centrifuged at 2000 rpm g for 10 minutes to remove the
liposomes adhered to the cell surface and analysed by flow
cytometry using a FACS LSR Fortessa (Becton Dickinson) and
FACSDiva software (BD Biosciences).
Immunization and challenge infection
All vaccines were formulated with cationic liposomes as
described previously. Six groups (35 hamsters/group for controls
and 25 hamsters/group for antigens) were immunized subcutane-
ously between scapulae at the back, two times at an interval of 2
weeks with or without liposomal antigens and 25 mg of MPL-
TDM (Sigma) in a total volume of 100 ml/animal/dose (Table S2,
supporting information). Groups 1, 2 and 3 received 2.5 mg of
rCPA (CPA/CL+MPL), rCPB (CPB/CL+MPL) and rCPC (CPC/
CL+MPL) respectively, entrapped in cationic liposome plus MPL-
TDM. Group 4 was immunized with the cocktail of liposomal
rCPA, rCPB and rCPC (2.5 mg of each protein) plus MPL-TDM
(CPA/B/C/CL+MPL). Control groups received PBS or empty
liposomes plus MPL-TDM. Ten days after the booster, five
animals/group were subjected to analysis of the cellular and
humoral responses after immunization (Table 2, supporting
information). The remaining hamsters were challenged intracar-
dially with 2.56107 freshly transformed stationary-phase promas-
tigotes in 200 ml PBS [20]. Immunological assays were carried out
post immunization and after 2 and 3 months of challenge
infection.
Measurement of body and organ weight of immunized
animals
The total body weight and that of liver and spleen (upon
sacrifice) were measured for all immunized groups on days 0, 60
and 90 days post challenge.
Delayed type hypersensitivity response (DTH)
Delayed type hypersensitivity (DTH) was determined 1 week
after boost and at 2 and 3 months post infection. DTH was
evaluated by measuring the difference in the footpad swelling at
24 h following intradermal inoculation of the test footpad with
5 mg of either rCPA, rCPB, or rCPC in a total volume of 50 ml,
and the swelling of the control (PBS injected) footpad with a
constant pressure caliper (Starrett Company, Athol, MA). For
cocktail immunized and control groups, DTH response was
evaluated by injecting the test footpad with a mixture of rCPA,
rCPB, and rCPC (total 5 mg).
Determination of rCPA, rCPB and rCPC -specific antibody
response
The levels of antigen-specific serum IgG and its isotypes, IgG1
and IgG2, were determined in serum samples from experimental
hamsters 10 days after the booster and at 2 and 3 months after
infection, by ELISA. In brief, 96-well microtiter plates (Maxisorp,
Nunc, Naperville, IL) were coated overnight at 4uC with rCPA/
rCPB/rCPC (5 mg/ml) singly or in combination (total 5 mg/ml)
for controls and cocktail vaccinates, diluted in 0.02 M phosphate
buffer (pH 7.5). For total specific IgG determination or IgG
subtyping, HRP conjugated goat anti-hamster IgG (1:8000,
Southern Biotech) or biotin-conjugated monoclonal mouse anti-
hamster IgG1 and IgG2 (1:1000, BD Pharmingen, San Diego,
CA) were used as secondary antibodies. The plates were blocked
with 1% BSA in PBS at room temperature for 3 h to prevent
nonspecific binding. The antigen-antibody reaction was detected
as described [26].The absorbance was measured using an ELISA
plate reader (Thermo, Waltham, MA) at 450 nm.
Evaluation of in vitro macrophage infection
Two weeks post immunization, macrophages (MW) collected
from peritoneal exudates of vaccinated hamsters were allowed to
adhere to glass cover slips in 0.5 ml RPMI 1640 media containing
10% FCS at 37uC in 5% CO2 as detailed elsewhere [26]. MW
were infected with promastigotes on glass cover slips (22 mm2; 106
MW/coverslip) at a ratio of ,10 parasites/MW. The unphagocy-
tosed parasites were removed by washing with warm PBS, and the
infected MW were further incubated in complete medium for 4,
16, 24, 48 and 72 h at 37uC in 5% CO2. The cells were then fixed
in methanol followed by staining with Giemsa for determination of
intracellular parasite numbers. Prior to fixation, culture superna-
tants were removed at the above mentioned time points and frozen
at 270uC for NO analysis.
Measurement of nitric oxide (NO) and reactive oxygen
species (ROS)
The production of nitric oxide (NO) in MW culture supernatants
was determined using the Griess reagent and the results were
expressed in mM nitrite [26]. Briefly, 100 ml of macrophage culture
supernatants were mixed with an equal volume of Griess reagent
(1% sulfanilamide and 0.1% N-1-naphthylethy-lene diamine
hydrochloride in 50% H3PO4) and incubated at room tempera-
ture for 10 min. Absorbance was then measured at 540 nm.
Intracellular reactive oxygen species (ROS) generation was
measured using the oxidant sensitive green fluorescent dye 29,
Cocktail Vaccination against Leishmania donovani
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79-dihydrodichlorofluorescein diacetate (H2DCFDA) (Molecular
Probes) [30]. For the experiments, differently treated and
untreated peritoneal macrophages were pre-stained with 10 mM
H2DCFDA (stock 10 mM solution in DMSO) for 30 minutes in
serum-free medium, followed by washing twice with fresh RPMI.
Fluorescence measurements were made using a microplate reader
(Synergy H1, BioTek; Excitation: 485 nm; Emission: 528 nm), in
triplicate and calculated as percent of control.
Cell proliferation assay
The spleen cells were aseptically removed from the immunized
hamsters 2 weeks after the last immunization and single cell
suspensions were prepared in RPMI 1640 as detailed elsewhere
[11]. The splenocytes were then washed twice, resuspended in the
culture medium and viable mononuclear cell number was
determined by Trypan blue exclusion [31]. The splenocytes were
labeled with carboxyfluorescein succinimidyl ester (CFSE) (Mo-
lecular Probes) using a slightly modified technique, originally
devised by Lyons et al. [32]. Briefly, 16107 cells/ml were
incubated with 2 mM CFSE for 10 min at 37uC. The labeling
was quenched by adding one volume of cold PBS and washed
twice in cold RPMI 1640 (Sigma). Then the cells were cultured in
triplicate in 24-well flat bottomed tissue culture plates (Nunc,
Roskilde, Denmark) at a density of 16106cells/well in a final
volume of 1 ml and stimulated with either rCPA, rCPB or rCPC
(5 mg/ml) singly for single antigen immunized groups or in
combination (5 mg/ml total) for controls and cocktail vaccinates or
conA (2.5 mg/ml). After five days, the cells were collected and
analysed on a FACSCanto flow cytometer (Becton Dickinson)
using the FACSDiva software.
Cytokine response
Complementary DNA was synthesized using SuperScript III
First-Strand Synthesis kit (Invitrogen, Grand island, USA) from
100 ng of total RNA isolated from splenocytes of differently
vaccinated hamsters using the RNeasy mini kit (Qiagen), before
and after 2 and 3 months of infectious challenge. Measurement of
levels of IL-2, TNF-a, IFN-c, IL-4, IL-10 and TGF-b was carried
out from splenocytes of vaccinated and control animals by a two-
step SYBR green I real-time reverse transcription PCR using
specific primers (Table S3, supporting information) as reported
earlier [33–35]. Conventional PCR using 100 ng of hamster
DNA, 300 nM cytokine specific primers and High Fidelity PCR
Enzyme Mix (Fermentas) was previously carried out in order to
optimize the real time PCR for each target. Hamster HGPRT
(Hypoxanthine-guanine phosphoribosyltransferase) was used as an
endogenous control to avoid variations between the samples. The
cDNA samples were subjected to an initial incubation for
10 minutes at 95uC and then 40 cycles of 95uC for 15 sec and
58uC for 30 s, and 72uC for 30 s in a 7900 HT Fast Real-Time
PCR System (Applied Biosystems). Each measurement was carried
out in triplicate. The relative expression of mRNA in terms of fold
change was calculated by the comparative Ct (22DDCt) method
[36] normalized to HGPRT expression. A no-template control
without genetic material was included to eliminate nonspecific
reactions.
Histopathology of livers of experimental animals
A part of liver from the sacrificed hamsters (2 months post
challenge) was used for tissue histology. After standard procedures
like paraffin embedding, histological sectioning and mounting on
glass slides, sections were stained with hematoxylin and eosin.
Sections from each liver (n = 3 hamsters per group) were examined
by counting 25 consecutive 406microscopic fields per section.
Evaluation of parasite burden in liver and spleen
After 2 and 3 months of challenge infection, the animals were
sacrificed to determine the parasite load in liver and spleen. The
course of organ parasite load was monitored by the microscopic
examination of Giemsa-stained impression smears of liver and
spleen, expressed as Leishman Donovan Units (LDU) [37] as well
as by limiting dilution assay (LDA) [38] as described previously.
For LDA, a weighted piece of liver and spleen isolated from
different vaccinated groups were homogenized and five-fold serial
dilutions of homogenized tissue suspension were cultured at 22uC
for 21 days in 96-well tissue culture plates (Nunc). The culture
plates were examined every 7 days for the presence of motile
promastigotes for 21days. The reciprocal of the highest dilution
that was positive for viable parasites was considered to be the
concentration of parasites per mg of tissue. The total organ
parasite burden was calculated using the weight of the respective
organs.
Statistical analysis
One-way ANOVA statistical test was performed to assess the
differences among various groups. Multiple comparisons Tukey-
Kramer test was used to compare the means of different treatment
groups using the GraphPad Prism 5.0 software for windows
(http://www.graphpad.com). The Kaplan-Meier method was
used to estimate survival rates, and the Log-rank test was applied
to compare the survivalities between different groups of hamsters.
A value of p,0.05 was considered to be significant for all analyses.
Accession numbers
Cysteine protease A (KF018070)
Cysteine protease B (KC609324)
Cysteine protease C (JX968801.1)
Results
Cloning of L. donovani cpa, cpb and cpc
Full length cpa, cpb and cpc were successfully cloned in the right
orientation in the bacterial expression vector pET28a and the
overexpressed proteins from E. coli BL21 (DE3) cells were purified
under denaturing conditions (Fig. 1 & S2). The molecular weights
of rCPA, rCPB and rCPC were approximately 38.8, 38.5 and
37.4 kilodalton (kDa) respectively. The yield of purified proteins
was approximately 3–5 mg per liter of culture. ClustalW analysis
shows 98–99% sequence homology of these three CP with the
different strains of L. donovani and L. infantum. Also, L. donovani
cpa, cpb and cpc were highly similar also to those of L. major cpa:
AJ130942.1 (64% identity), cpb: U43706.1 (88% identity) and cpc:
XM_003722109.1 (95%) respectively. Phylograms depicting the
phylogenetic relationships of cpa, cpb and cpc among different
Leishmania species are shown in Fig. S1 (supporting information).
After successful entrapment in cationic liposomes, the level of
incorporation ranged between 70–80%. Protein integrity after
liposomal encapsulation was evaluated by 10% SDS-PAGE
followed by Coomassie staining. Positive reactions of all three
recombinant proteins CPA, CPB and CPC with anti-His
monoclonal antibody in Western blot analysis identified these
proteins from bacterial lysates (Fig. 1C).
Recombinant CPs are highly immunoreactive in cured
and active VL patients
To determine the presence of antibodies against L. donovani
CPs in human VL, rCPA, rCPB and rCPC were subsequently blot
checked against a panel of plasma samples from kala-azar patients.
Cocktail Vaccination against Leishmania donovani
PLOS Neglected Tropical Diseases | www.plosntds.org 5 August 2014 | Volume 8 | Issue 8 | e3091
Blood plasma isolated from patients infected with L. donovani
recognized all the three recombinant proteins (rCPA, rCPB and
rCPC) separately at 1:1000 dilution (Fig. 1, E–G). This finding
verified the reactivity of the selected proteins in both active and
cured VL patients, but not in healthy controls. Recognition of L.
donovani CPs also by Brazilian VL (L. chagasi) patient plasma
(data not shown) is predictive of cross-protective potential of these
vaccine candidates and also for diagnosis of kala-azar.
Characterization of liposomal delivery system
AFM in the acoustic alternative current mode allows the
observation of the liposomal surface morphology and structure,
overcoming sample manipulation (Fig. 2). Flattening of vesicles on
the mica support few minutes after deposition indicates a
moderate stability of the liposomes. AFM images clearly depict
the spherical, well-defined shape of the liposomes with visible
multilamellar structures and heterogeneous size distribution,
which is also maintained after protein loading (rCPC taken as
reference) (Fig. S4). Size of the vesicles ranged between 137–172
(614.3) nm.
Cellular uptake and antigen delivery by cationic
liposomes
Among all APCs, MWs play a central role in processing of
liposomal antigens in lysosomes for successful Ag presentation to T
cells [39–44]. To expand on that, we investigated intracellular
trafficking patterns of our cationic liposomes as well as their
mechanism of internalization in hamster peritoneal MW in vitro
(Fig. 2D & S3). LysoTracker Red was used as a fluorescent
acidotrophic probe for tracking acidic organelles in MW. Confocal
laser scanning microscopy (CLSM) of MW cells incubated for 2 hrs
with both Rh123-labeled liposomes (green), LysoTracker Red (red)
and DAPI(blue) simultaneously showed successful co-localization
(yellow) of labeled liposomes in acidic compartments such as
lysosomes (Fig. S3, B) which confirms antigen presentation by MW.
For a quantitative insight into the various potential mechanisms of
endocytosis, a series of liposome uptake assays were performed in
the presence of different inhibitors (amiloride, chlorpromazine,
cytochalasin D and colchicines) to block each individual pathway.
The use of amiloride (macropinocytosis inhibitor) and chlorprom-
azine (clathrin-mediated endocytosis inhibitor) strongly inhibited
the uptake of cationic liposomes by ,31% (62.674) and ,29%
(61.07) respectively (Fig. 2D). We deduce partial overlap or
synergistic involvement of these pathways for liposomal uptake in
hamster peritoneal MW. By contrast, cytochalasin D and
colchicines had only minimum effect on the cellular entry of
liposomes indicating minor contributions of actins and microtu-
bules in the uptake process. Nevertheless, other unidentified
pathway(s) of endocytosis may also be involved in liposome
trafficking through MW. The FACS estimation of the inhibitory
effects on internalization and post-endocytic trafficking of labeled
liposomes further confirmed the CLSM data (Fig. S3, A).
Cationic liposomes with MPL-TDM activates the MW
innate immunity by NO and ROS-dependent mechanisms
in vitro
To evaluate innate capacity of our adjuvant formulation to
stimulate MWs, naı¨ve peritoneal MWs were isolated and stimulated
with bacterial lipopolysaccharides (LPS) (1 mg/ml), cationic
liposomes (50 mM), MPL-TDM (100 ng/ml) and combination
of cationic liposomes (50 mM) and MPL-TDM (100 ng/ml)
(Fig. 2, E & F). MPL-TDM alone activates MWs from naı¨ve
Figure 1. Cloning and expression of cpa, cpb and cpc. A, Coomassie blue stained protein fractions showing overexpression of cpa, cpb and cpc
in E. coli BL21 (DE3). Lane 1, prestained molecular weight marker; lane 2, cpa; lane 3, cpb; lane 4, cpc. B, Coomassie blue staining of 10% SDS-PAGE
showing purified proteins. Lane 1, molecular weight marker; lane 2, rCPA; lane 3, rCPB and lane 4, rCPC. C, recombinant proteins probed with anti-
polyhistidine antibody after Western blot. Lane1, molecular weight marker; lane 2, rCPA; lane 3, rCPB and lane 4, rCPC. D–F, Plasma recognition of L.
donovani CP. Immunoblot analysis of recognition of recombinant CPA (D), CPB (E) and CPC (F) by human blood plasma from infected (odd numbered
lanes 1–7) and cured (even numbered lanes 1–7) individuals suffering from VL. Lane 8–12, endemic controls. M, molecular weight marker.
doi:10.1371/journal.pntd.0003091.g001
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hamsters resulting in increased NO and ROS production, which
are regarded as the potent microbicidal molecules responsible for
parasite clearance from infected MWs [45]. Evidence for such
endotoxin and lipid A mediated NO production via inducible
iNOS is increasing [46,47] which results in innate host cell
activation and subsequent adjuvant properties. The significant
production of NO (Fig. 2E) and ROS (Fig. 2F) in response to
cationic liposomes along with MPL-TDM are in agreement with
our previous study which showed that stimulation of murine DCs
with liposomes plus MPL-TDM could enhance IL-12 (p40) and
NO generation in vitro [11]. These data indicated that combining
MPL-TDM with cationic liposomes result in increased the
adjuvant activity of the formulation on the APCs in vitro, serving
our rationale for its utilization.
Figure 2. Particle characterization, cellular uptake and localization of cationic liposomes in hamster macrophages (MWs). A–C,
tapping mode AFM images of liposomes obtained 15 mins after deposition on mica support. A, AFM image presented as two-dimensional graphics
showing the clean spherical shaped DSPC-liposomes. Amplitude-flattened views of liposomes are shown. B, 3D images of DSPC-liposomes by AFM
study. C, horizontal cross sections indicating the height of the liposomes from the substratum, i.e., the mica sheet. D, Elucidation of cellular uptake
mechanisms of cationic DSPC-liposomes in MWs. Percent uptake of Rh-123 (green) labeled liposomes is shown in hamster peritoneal MWs treated
with or without different biochemical inhibitors, studied by flow cytometry. Data represent the mean and standard deviation of three different
experiments performed in duplicate (***p,0.001, compared to no-inhibitor control). E–F, Activation of innate response towards cationic liposomes
and MPL-TDM. Hamster peritoneal MWs were isolated and stimulated with LPS (1 mg/ml), liposomes (50 mM), MPL-TDM (100 ng/ml) and
combination of liposomes (50 mM) and MPL-TDM (100 ng/ml). The release of NO (E) and ROS (F) were measured subsequently. The data are
representative of three independent experiments with similar results.
doi:10.1371/journal.pntd.0003091.g002
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DTH and antibody response as a measure of vaccine
induced protection
DTH was measured as an index of in vivo elicitation of cell-
mediated immunity. All the CP immunized hamsters displayed
steady increase in DTH response, both before and 2 and 3 months
after infection. Among the three antigens, liposomal rCPC
vaccination induced maximum DTH followed by rCPB and
rCPA at 3 months post challenge. Highest DTH was obtained for
cocktail vaccinates (Fig. 3A; p,0.0001compared to free adju-
vants), which was even significantly higher than rCPC (p,0.0001)
vaccinated hamsters post vaccination as well as at 2 and 3 months
post infection. Serum samples were analyzed for total IgG, IgG1
and IgG2 both before and after infection in vaccinated animals.
Although distinct IFN-c and IL-4 mediated IgG isotype switching
is not reported in hamsters, IgG1 and IgG2 are still considered as
surrogates of Th2 and Th1 response similar to murine IgG1 and
IgG2a/b respectively [48]. Shown in Fig. 3 are the antibody levels
in immunized (Fig. 3B) and 3 months post challenged (Fig. 3C)
hamsters (sera dilution 1:1000). In comparison to controls,
significant enhancement of antigen-specific total IgG, IgG1 and
IgG2 with a dominance of IgG2 was observed in all antigen
immunized hamsters. Contrastingly, after infection, the levels of
IgG2 were quite low in hamsters receiving PBS or free adjuvants
as controls indicating a Th2 response favouring disease progres-
sion. All CP immunization induced higher specific IgG2 titers than
IgG1, with significant difference observed between the IgG2
subclasses in single antigens and cocktail vaccination schedule
(Fig. 3B). Remarkable IgG2 dominance was observed in hamsters
receiving rCPC and triple antigen cocktail which also differed
significantly between rCPC and cocktail immunized groups
(p,0.01) (Fig. 3B & C). The results were consistent with
lymphoproliferation and Th1 biased cytokine response, which
showed strong CMI response in animals receiving rCPC and
cocktail antigens.
Mitogenic and antigen specific lymphoproliferation in
vaccinated hamsters
Impaired T-cell mediated immunity as assessed by in vitro
lymphocyte proliferation has been the hallmark of progressive VL
[49,50]. Proliferative capacity is a wanted feature of vaccine,
reflecting stimulation of T cell responses. Therefore, to gain insight
into cellular immunity developed in hamsters after vaccination,
antigen specific splenocyte proliferation was evaluated using
CFSE. As shown in Fig. 4, ConA (mitogen), taken as a positive
control, highly enhanced cell proliferation. Splenocytes from all
the CP vaccinated hamsters proliferated in response to corre-
sponding antigen. Among the three CPs, rCPC showed higher
antigen-specific proliferation compared to rCPA and rCPB.
Significant enhancement of antigen-specific splenocyte prolifera-
tion was observed for liposomal rCPC (p,0.001) and liposomal
cocktail (p,0.0001) vaccinated animals compared to adjuvant
controls. Highest percent lymphoproliferation was observed in
hamsters vaccinated with triple antigen cocktail which was
significantly higher than rCPA (p,0.0001), rCPB (p,0.0001)
and rCPC (p,0.0001) as single antigen. Taken together, these
finding suggest that all three CPs present in the cocktail vaccine act
synergistically to counteract the impaired T cell response after
challenge for improved protection.
In vitro antileishmanial activity of peritoneal
macrophages
MW have long been known to play an important role in
leishmanicidal activity through IFN-c and IL-12 mediated
production of NO [51]. However, like human, NO generation
in infected hamsters is severely impaired due to lack of IFN-c
mediated upregulation of nitric oxide synthase (NOS) 2 mRNA
[52]. To evaluate the vaccine-induced activation of MW to
arrest parasite multiplication, the number of intracellular
amastigotes and NO production were determined in resident
peritoneal MW from different immunized groups at designated
time points (4 hr, 16 hr, 24 hr, 48 hr and 72 hr) after in vitro
infection with L. donovani (Fig. 5). No significant difference
was observed between groups in the numbers of initial uptake
and percent infected MW till 24 h of incubation (Fig. 5A).
However, after 48 and 72 h, significant leishmanicidal activity,
lowering of percent infected MW (Fig. 5A) and mean number
of amastigotes/MW (Fig. 5B) was observed in all CPs immu-
nized animals compared to controls. Of interest, maximum
inhibition of parasite multiplication in vitro was observed in
hamsters receiving rCPC and cocktail antigens (p,0.0001)
which was even significantly higher than liposomal rCPA (p,
0.0001) and rCPB (p,0.0001) vaccinates, sustained upto 72 h
of incubation (Fig. 5B). However, no significant difference in
amastigote killing activity was noted between rCPC and
cocktail vaccinates after 72 h. This may be due to the reason
that control of in vitro infection by MW is not solely due NO
production but also by the milieu of cytokines and chemokines,
specially IL-12 and TNF-a secreted by the parasitized APCs
[53]. Almost comparable levels of these may also account for
the lack of significant difference in parasite clearance between
rCPC and cocktail vaccinates in vitro. NO level in single
antigen vaccinates were almost comparable without significant
difference between the groups upto 48 h, but was significantly
upregulated in rCPB and rCPC vaccinated animals at 72 h
post infection compared to controls (Fig. 5C). Interestingly,
MW from liposomal cocktail antigen immunized animals
released the highest amount (7 mM) of NO which was ,4.3
fold more than that of infected controls and ,2-fold more than
the single antigen (rCPA, rCPB, rCPC) immunized groups
after 72 h post culture. Collectively, immunization with
liposomal cocktail CPs mounted highest antileishmanial
activities towards L. donovani infected MW, followed by
liposomal rCPC.rCPB.rCPA, immunized animals.
Histopathological studies
The degree of cellular response in terms of granuloma
formation in liver of immunized and infected control hamsters
indicates the histological features of either parasite clearance or
multiplication in this organ [54]. Considerable variation among
animals between different groups was observed in hepatic
histology 2 months after L. donovani challenge (Fig. S6). In the
infected controls the cellular response in liver was restricted to few
immature granulomas, comprising of fused infected Kupffer cells
with a large number of infiltrating lymphocytes and histiocytes.
The histological features in controls were indicative of suboptimal
cellular response inappropriate for parasite clearance. Occasional
portal tract inflammation, fibrosis and hepatocyte degeneration
resulting in loss of normal tissue architecture were also visible in
liver of infected controls. Mature granulomas with compact
collection of cellular infiltrates, indicative of optimal cellular
response leading to parasite clearance, were mostly seen in groups
immunized with cocktail and liposomal rCPC vaccinated animals
(Fig. S6, A). Figure S6, B shows a magnified view of a
representative granuloma assembly in a cocktail immunized
hamster, showing cellular infiltration of lymphocytes and mono-
cytes.
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Vaccination with CP cocktail generates optimum
protection in hamsters against L. donovani challenge
Weight loss and hepatosplenomegaly in infected controls, as a
normal course of progressive VL was evident from 2 months of
infection (Fig. S5). Fig. 6A–D shows the outcome of vaccination
on parasite burden in liver and spleen at 2 and 3 months post
infection. In all the CP vaccinated groups, parasite load in spleen
sharply decreased after 2 and 3 months of infection compared to
controls. At 3 months post infection, significantly high yet
comparable level of protection was induced by rCPA and rCPB
immunized groups, suggesting a specific partial protection induced
by these antigens compared to controls (p,0.0001). rCPC induced
greater protection than both rCPA and rCPB, when injected
alone. Of interest, the mean hepatic and splenic parasite burden
(LDU) were lowered by,93% and ,98% respectively, in animals
immunized with cocktail antigens as compared to the adjuvant
controls at 3 months post infection. Significantly higher protection
was obtained using the cocktail vaccine compared to the single
antigens: rCPA (73%), rCPB (76%) but not rCPC (91%) in spleen.
Our result obtained in LDU was reconfirmed through limiting
dilution assay, LDA (Figure 6, C & D), the more sensitive method
for monitoring viable parasites. Free adjuvant (CL+MPL) itself
generated some protection resulting in 2.46 log106.61 in the liver
and 1 log1061.66 in the spleen at 3 months post challenge. This
was, however, not significant compared to PBS controls. After 3
months post infection, hamster immunized with liposomal rCPA
and/rCPB showed reduced parasite burden ,6.5–9 log-folds in
liver and ,8.8–10 log-folds in spleen, respectively, compared to
animals immunized with adjuvant alone (Figure 6, C & D).
Immunization with rCPB thus resulted in better protection than
rCPA in clearing the parasites from visceral organs. Interestingly,
hamsters vaccinated with liposomal rCPC showed a parasitic
Figure 3. Pre and post challenge cellular and humoral responses in vaccinated hamsters. A, DTH response before and after 2 and 3
months post infection. B, serum IgG, IgG1 and IgG2 at 10 days after final vaccination. C, IgG, IgG1 and IgG2 response after 3 months post infection.
Data are presented as the mean absorbance at 450 nm 6 S.E., ***, p,0.0001, ns = not significant. Asterisks over each bar indicate significant
differences in comparison to adjuvant controls. Asterisks over line indicate significant differences between groups. *, p,0.05; **, p,0.01. The results
are mean 6 S.E. of five individual hamsters per group, representative of two independent experiments with similar results.
doi:10.1371/journal.pntd.0003091.g003
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Figure 4. Proliferative response in hamsters vaccinated with liposomal CPs with MPL-TDM. Splenocytes from immunized animals were
labeled with CFSE (2 mM) and restimulated in vitro for 5 days with 5 mg/ml of specific antigen or 2.5 mg/ml ConA. Antigen-specific splenocyte
proliferation of individual animals was analyzed by flow cytometry and CFSE dilution on gated cells. A, Gating strategy for hamster lymphocytes and
CFSE high and CFSE low populations. B, Representative histogram showing percent proliferation, calculated in the indicated region (bar). C, the bar
graphs show mean percent proliferation of the lymophocytes, which is inversely proportional to cell divisions. The data are representative of one
Cocktail Vaccination against Leishmania donovani
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burden of 5.963 log1060.269 in the liver and 6.77 log1060.463
in the spleen, with an impressive 4 (log10)-fold decrease in the
parasite burden compared to hamsters receiving liposomal rCPA
(9.55 log1061.037 in the liver and 11.5 log1060.467 in the
spleen, p,0.0001) and 2 (log10)-fold reduction compared to
liposomal rCPB (7.413 log1060.016 in the liver and 10.02
log1060.451 in the spleen, p,0.0001). Highest level of protection
against L. donovani was however achieved in hamsters immunized
with the liposomal triple antigen cocktail which showed 13 log-fold
and 16 log-fold reductions in the parasite burden in liver and
spleen, respectively, compared to adjuvant controls (p,0.0001)
after 3 months of infectious challenge. Moreover, they exhibited
minimal weight loss and the surviving animals appeared appar-
ently healthy till the termination of the experiment. Consequently,
almost 80% survival was observed in hamsters injected with the
cocktail vaccine for at least 180 days post infection (Fig. 6E). In
contrast, almost 50–60% of the controls died after 3 months due to
steady increase in parasite load (Fig. 6E).
In-vivo immunomodulation
In experimental VL, the efficacy of antileishmanial prophylaxis
chiefly depends on CMI and balanced production of endogenous
Th1 and Th2 cytokines [55]. The cytokine expression profiles of
vaccinated and control infected hamsters were thus dissected to
find out their role in immunoprotection. All immunized groups
receiving either of liposomal rCPA, rCPB and rCPC singly or as
cocktail produced significant upregulation of IL-2 and IFN-c
mRNAs in comparison to controls, which progressively increased
at 2 and 3 months post infection (Fig. 7A). rCPA and rCPB
immunizations although showed heightened IFN-c and IL-12
animal from two experiments with at least three hamsters in each group. Significant differences between means are indicated: *, p,0.05; **, p,0.01
compared to PBS controls.
doi:10.1371/journal.pntd.0003091.g004
Figure 5. Anti-leishmanial activity of macrophages from liposomal CP immunized hamsters. A, Percentages of infected peritoneal MWs
from different groups of hamsters from different liposomal CP immunized groups after infection with L. donovani promastigotes. B, Total number of
amastigotes/1000 peritoneal MWs in vitro after immunization with liposomal cysteine proteases after 4 h, 16 h, 24 h, 48 h and 72 h infection with L.
donovani. C, NO production by infected MWs after 4 h, 16 h, 24 h, 48 h and 72 h of in vitro infection. The results are mean 6 S.E. of five individual
hamster per group, representative of two independent experiments with similar results. Statistically significant (*, p,0.01; **, p,0.001;***, p,0.0001)
differences in MW infection, parasite multiplication and nitrite production were compared to PBS controls. Asterisks over line indicate significant
differences between groups.
doi:10.1371/journal.pntd.0003091.g005
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Figure 6. Protection and survival against L. donovani infection in immunized hamsters. A–D, kinetics of liver (A) and spleen (B) parasite
burden by LDU, liver LDA (C) and spleen LDA (D) of hamsters 2 and 3 months after intracardiac challenge of 26107 virulent L. donovani
promastigotes. Results are expressed as log of total organ parasite burden. Data represent the mean 6 S.E. (n = 5/group). ***p,0.001 compared to
adjuvant controls. Asterisks over line indicate significant differences between groups. E, Kaplan-Meier survival curves comparing survivality in
different groups of vaccinated hamsters. Survival results are from 10 hamsters per group. Survival distribution was analyzed by log-rank (Mantel-Cox)
test, and level of significance is indicated by P value.
doi:10.1371/journal.pntd.0003091.g006
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expression, also enhanced expression of disease promoting
cytokines like IL-4 and IL-10 mRNAs after infection, which
perhaps limited their vaccine efficacy. The splenocytes of
vaccinated hamsters receiving liposomal rCPC and cocktail of
three liposomal CPs showed higher IFN-c, IL-2, TNF-a and IL-12
mRNA expression than all other groups but appreciable
downregulation of macrophage deactivating cytokines like IL-4,
IL-10 mRNAs, before and after infection (Fig. 7). Even after 3
months post infection, an appreciable ,4.5 fold and ,3.5 fold
upregulation of IFN-c (p,0.001) and IL-12 (p,0.001) mRNAs
respectively were observed in cocktail immunized animals
compared to PBS controls. There were 9 to10-fold reductions in
IL-10, for rCPC and cocktail immunized groups (p,0.0001) after
3 months post infection (Fig. 7 D) compared to adjuvant controls
which was directly related to disease progression. Further analysis
of the induced cytokine expression by the means of IFN-c/IL-10
mRNA ratio (not shown) revealed that liposome formulated
cocktail CP vaccines clearly induced a strongest Th1 response in
comparison to all other groups, required for sustained protection.
Further, augmented level of disease-resolving cytokine, TNF-a
mRNA (Fig. 7, C & F), notably high in rCPB, rCPC and cocktail
vaccinated groups corroborate intracellular parasite killing. In
particular, a dramatic shift towards Th1 phenotype and most
probably an effective CMI response was maintained by high IL-12
and IL-2 mRNA levels even at 3 months post infection in cocktail
vaccinates. Although we could not dissect the T cell phenotype
responsible for protective immunity, results from antigen-specific
T-cell proliferation, NO production, increased mRNA expression
of IL-2, IL-12, IFN-c, robust DTH responses, and IgG2 antibody
titer are indicative of durable T-cell response which is sustained at
least up to 3 months post infection. Further, our results emphasize
a major role of IL-10 and IL-4 upregulation for disease
progression and death in infected controls, probably mediating
their effect through IFN-c blocking, macrophage deactivation and
lymphocyte apoptosis as reported earlier [56,57].
Discussion
Till date, ‘leishmanization’ remains the gold standard for
vaccination against leishmaniasis for providing long term protec-
tion. However, safety concerns and anti-vector immunity have
complicated the development of live vaccines against Leishmania
[58]. In contrast, a non-living subunit vaccine containing selected
antigens combines safety and rational designing to target the
intracellular pathogens, avoiding anti-vector immunity. However,
subunit protein vaccines without adjuvant often suffer from limited
or non-existent T cell response due to poor antigen presentation
via APCs [59,60]. Interestingly, current prophylactic vaccine
strategies against intracellular pathogens like Leishmania focus on
strengthening host innate immunity that target the pathogen, in
addition to vaccine induced adaptive response [61]. Vaccination
against Leishmania requires both innate and adaptive arms of host
defence mediated through MW, dendritic cells and both CD4+ and
CD8+ T cells for protection [62,63]. The liposomal cargos loaded
with protein antigens in combination with defined immunostimu-
latory molecules mimicking pathogens in reductionist mode are
attractive formulations to elicit protective T cell immunity. Use of
TLR agonists with cationic liposomes allows concurrent antigen
presentation along with targeting pattern recognition receptor
(PRR) pathways, for effective expansion of effector T cells [64,65].
In this study we therefore selected highly immunostimulating
adjuvant formulation (cationic liposomes and MPL-TDM) to
investigate the ability of leishmanial CPs to generate both humoral
and cell mediated immune response via subcutaneous route.
Lysosomal cysteine proteases (CP) are reported to be involved in
distinct cellular functions and make safe vaccine antigens against
Leishmania [15–17]. Nevertheless, evaluation of protective effica-
cies of these proteins against L. donovani is lacking. The present
study compares the efficacies of three recombinant cysteine
proteases (rCPA, rCPB, rCPC) and their cocktail using cationic
liposomes with MPL-TDM adjuvant platform for the first time
against L. donovani. Hamsters are well-established animal models
for L. donovani infections, with high innate susceptibility and
clinicopathological resemblance to human VL [66], thus suitable
for evaluation of vaccines for human use.
Macrophages, the major intracellular niche for Leishmania, are
also involved in antigen presentation and vaccine-induced
leishmanicidal activity, usually predictive of disease outcome in
vivo. Phagocytosis by macrophages plays an important role in
lymph node retention of liposomes after subcutaneous immuniza-
tion [67,68]. Cellular internalization and successful endosomal/
lysosomal loading for MHC class II antigen presentation via APCs
has been studied for the first time for DSPC bearing cationic
liposomes showing involvement of distinct endocytic pathways
(macropinocytosis and clathrin-mediated) (Fig. 2) for cellular
entry. This is advantageous in lowering the amount of vaccine
Ag by liposomal encapsulation enabling administration of higher
effective doses if required [26].
Impaired cellular immunity along with a shift towards Th2-
type immunity has been the hallmark of VL [50]. Although the
role of humoral response in resolution of VL is controversial,
elevated level of IgG after infection usually correlates with VL
progression in hamsters. The rapid increase in anti-leishmanial
IgG observed after antigen immunization appeared to result from
associated MPL-TDM which is known to augment humoral in
addition to CMI response [69]. However, the sustained domi-
nance of IgG2 over IgG1 in CP vaccinated animals indirectly
reflects the Th1-biased protective immune responses at 2 and 3
months post challenge. This is in accordance with enhanced
proliferation of hamster splenocytes isolated from cocktail
vaccinated group over nonvaccinated and single antigen immu-
nized animals.
In VL, a balance must be established between Th1 and Th2
cytokines for parasite clearance. High IL-10 and IL-4 can lead to
disease exacerbation and vaccine failure even in presence of high
IFN-c [70]. TNF-a, another well-defined inflammatory cytokine
with antileishmanial properties, is known to act either alone or
with IFN- c to induce the production of NO and ROS and might
have a strong additive effect in clearing parasites from vaccinated
animals. All three CPs immunizations resulted in increased level of
IL-12 driven IFN-c, but low amounts of IL-4, IL-10 and TGF-b.
Thus, enhanced IL-2, IL-12, TNF-a and IFN-c mRNA expression
but downregulation of IL-10, most remarkable in cocktail
vaccinated hamsters is chiefly responsible for strong Th1 biased
immunity after infection [71]. Interestingly, IL-10 is also generated
at low levels after infection as a part of effector response to prevent
autoimmunity and maintenance of T cell proliferation [72].
Significantly low but consistent mRNA expression for both IL-4
and IL-10 in all CP vaccinates, more noticeably in rCPC and
cocktail immunized groups, probably circumvents uncontrolled
Th1 response and tissue damage due to high post-challenge IFN-c
and IL-12 expression levels in these groups. Of interest, hepatic
histology, in vitro lymphoproliferation and NO mediated clear-
ance of parasites from MW nicely correlates with in vivo protection
after virulent challenge. Maximum number of matured hepatic
granuloma was observed in rCPC and cocktail immunized
hamsters after 2 months which led to almost complete clearance
of parasites from visceral organs. The combination of CPA, CPB
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and CPC resulted in enhanced protection in liver (.93%) and
spleen (.98%) which was even higher than all other CPs based
vaccines tested against Leishmania so far [15–17]. Previous
vaccine attempts with different liposomal adjuvants have reported
remarkable efficacy of about 80–90% protection against Leish-
mania [73] and other pathogens [74,75]. Liposome entrapped
native LD51 (b-tubulin) and LD31 (ATP synthase a-chain) from
L. donovani induced 75–77% protection in mice, through
intraperitoneal route [73]. Similarly, 7–10-log-fold reduction in
parasite burden upon was obtained upon vaccination with
liposomal recombinant gp63 with MPL-TDM in mice [11]. One
plausible explanation for the synergistic enhancement of protec-
tion with cocktail CP vaccination is the cumulative increase in T-
cell epitopes in a non-antagonistic manner. In this context, it is a
known that the parasite CPA, CPB and CPC all belong to the
same group of papain-like CPs, and probably behave like a multi-
subunit vaccine when given in combination. Enhanced Th1
dominance in the current study chiefly arises from the associated
MPL-TDM within the liposomal formulation, increasing the
efficacy and adaptability of the delivery system as reported earlier
in mice [11]. MPL is known for its direct interaction with TLR4
on dendritic cells (DC) influencing IL-12/IFN-c axis, to skew the
T cell response towards a Th1-phenotype [76,77]. Taken together,
vaccination with liposomal CPs combined with MPL-TDM
confers a Th1 biased mixed Th1/Th2 response to reduce the
parasite burden in hamsters. Although, direct comparison of our
work with previous reports is difficult, it is noteworthy that rCPC
individually induced better protection than promising vaccine
candidates like gp63, ORFF, LelF-2 tested in murine VL [78]
against L. donovani. Hence, we propose that combining rCPC or
its antigenic motif with other immunodominant antigens as
cocktail or fusion hybrid can induce durable and complete
protection against VL. Here we report almost complete elimina-
tion of parasites from both liver (16-log fold) and spleen (13-log
fold) after vaccination with CP triple antigen cocktail and L.
donovani virulent challenge. Though sterile protection was not
achieved, the efficacy of this antigenic cocktail is quite high
compared to other subunit protein vaccinations tried against
experimental VL [79,80] and needs further optimization. Finally,
one clinical consequence of this work is that the protective
Figure 7. Th1/Th2 cytokine profiles of immunized hamsters at different time intervals pre- and post-infection by quantitative real-
time–PCR. Fold change in mRNA expression profiles of A, IFN-c; B, IL-12; C, TNF-a; D, IL-4; E, TGF-b; F, IL-2; G, IL-10. Each gene was normalized to the
housekeeping gene (Hypoxanthine-guanine phosphoribosyltransferase, HGPRT) to avoid variations between different samples. Results are expressed
as the mean 6 S.E. of five hamsters individually assayed from each group. *, p,0.05; **, p,0.01;***, p,0.001 assessed by one-way ANOVA and
Tukey’s multiple comparison tests.
doi:10.1371/journal.pntd.0003091.g007
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antigen(s) might not be the only determinant of protection but also
require highly immunopotentiating adjuvant to realize its full
potential.
The development of a long-term protective immunity in terms
of CD8+ T cells response is extremely important for successful
vaccination against intracellular pathogens like Leishmania. In the
recent past, many protein subunit vaccines that reported various
levels of protection against Leishmania, often failed to generate
sufficient long term memory against the disease [81]. Although,
rHASPB1, rORFF, Leish-111f, and Leish-110f have reported
sustained long term immunity against VL, they suffered either
from using human incompatible adjuvant [82] or from low level of
protection [83]. Importantly, Leish-111f and Leish-110f formu-
lated with MPL-SE were human compatible, but did not show
data for protection in both liver and spleen were not reported
[82,83]. Moreover, all these studies carried out in mice, challenged
the vaccinated animals 3–4 weeks after the last boost. Our
previous reports with crude leishmanial membrane antigen (LAg)
[84] and native gp63 [85] entrapped in positively charged
liposomes showed significant long term protection when chal-
lenged with virulent parasites 10–12 weeks after final immuniza-
tion. However, one of the major drawbacks of these studies was the
use of intraperitoneal route of immunization, not suitable for
human use. This problem was overcome with the use of MPL-
TDM adjuvant which could prime both CD8+ and CD4+ T cells
when used in subcutaneous route with liposomal antigens: soluble
leishmanial antigen (SLA) [86] and recombinant gp63 [11],
leading to both short-term and long-term protection. The above
results obtained so far and our preliminary survival analysis data in
the present study do indicate an appreciable long-term protective
response generated by the cocktail CPs formulated with MPL-
TDM which was sustained at least up to 180 days post infection in
hamsters. Unfortunately, mechanistic details of CD4+, CD8+ and
regulatory T cells involved in vaccine mediated protection cannot
be fully elucidated due to unavailability of hamster-specific
reagents. This can be overcome with mice model in future which
is the focus of our continuing research efforts.
Supporting Information
Figure S1 Phylogeny of L. donovani cysteine proteases.
A–C, Phylogram showing evolutionary relationship of cysteine
protease A (A), B (B)and C(C) of different strains of Leishmania (L.
infantum, L. chagasi, L. mexicana, L. braziliensis, L. tropica, L.
aethiopica, L. major and L. donovani) with three different
cathepsins in Homo sapiens at DNA level, using ClustalW Multiple
Alignment in the FASTA format. The accession numbers of
cysteine protease sequences used in the phylogenetic analysis are
given in parentheses.
(TIF)
Figure S2 Cloning of cpa, cpb and cpc from L. donovani.
A, lane 1–4, genomic DNA isolated from L. donovani (MHOM/
IN/83/AG83) promastigotes. B, PCR amplification of cpa, cpb
and cpc from L. donovani genomic DNA. C, cloning of cpa in
pET28a vector. Lane 1, insert cpa (1.062 kb); lanes 2–5, NdeI/
HindIII digested pET28a-cpa (vector size is ,5 kb). D, cloning of
cpb in pET28a vector Lane 1, insert cpb (1.335 kb); lane 2–5,
NdeI/HindIII digested pET28a-cpb constructs. E, Cloning of cpc
in pET28a vector. Lane 1, NdeI/HindIII digested pET28a-cpc;
lane 2, insert cpc (1.038 kb); lane 3 and 4, PCR from positive
clones pET28a-cpc.
(TIF)
Figure S3 CLSM study of cellular localization of cation-
ic liposomes in macrophage. A, Elucidation of uptake
mechanisms of Rh-123 (green) labeled cationic liposomes in
hamster peritoneal MWs treated with or without different
biochemical inhibitors, studied by CLSM. Cell nuclei were stained
with DAPI (blue). B, 3D confocal image showing colocalization of
liposomes labeled with Rh-123 (green) with endosomes/lysosomes
were labeled with LysoTracker Red (red) after 2 h of incubation
with hamster peritoneal MWs. White arrows indicate the occasions
of coincidence (yellow: merge of red and green fluorescence)
between the liposomes and endosome/lysosomes. Scale bars,
10 mm.
(TIF)
Figure S4 Tapping mode AFM images of protein laden
DSPC liposomes. A, AFM images represented as two-
dimensional graphics showing the clean spherical shaped lipo-
somes encapsulating antigen (rCPC as reference protein). B, 3D
image of the same liposomes. C, horizontal cross section indicating
the height of the liposomes from the substratum.
(TIF)
Figure S5 Protection against L. donovani in immunized
hamsters. A, Body weights before and at 2 and 3 months after
challenge. Liver (B) and spleen (C) weight of immunized hamsters
at designated time points after challenge. C, Upper panel shows
representative image of spleens of different vaccinated groups at 3
months post infection.
(TIF)
Figure S6 Hepatic histology sections stained with
hematoxylin and eosin 2 months after challenge infec-
tion. A, Liver architecture of normal and infected hamsters in
comparison with immunized groups as indicated in at 2 months
post-infection (upper panel magnification 610; lower panel
magnification640). B, Mature granuloma assembly (magnification
6100) in cocktail cysteine protease immunized animal. The results
are representative of two independent experiments, for 3
individual hamsters per group.
(TIF)
Figure S7 Evaluation of protection in hamsters at 3
months post infection. A, DTH responses in free CP-
immunized (without adjuvant) hamsters expressed as the differ-
ences (in millimeters) between the thicknesses of the test (antigen-
injected) and control (PBS-injected) footpads. Results are shown as
means 6S.E. for five animals per group and are representative of
two independent experiments with similar results. B, Parasite
burden (LDU) in the spleen at 3 months postinfection in hamsters
immunized with CPA, CPB, CPC or cocktail with or without
liposome adjuvant system. Data represent the mean 6S.E of five
individual animals per group, representative of two independent
experiments with similar results. P-values were assessed by
Student’s two-tail t test.
(TIF)
Materials and Methods S1 Fixed-cell confocal laser
scanning microscopy (CLSM).
(DOC)
Table S1 Primers used to amplify cpa, cpb and cpc
from L. donovani (restriction sites underlined).
(DOC)
Table S2 Experimental design for vaccination.
(DOC)
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Table S3 Sequence of forward and reverse primers
used for quantitative real-time RT-PCR of cytokines
from hamster.
(DOC)
Acknowledgments
We are thankful to S. Roy, Director of IICB, Kolkata, for supporting this
work. We thank Roma Sinha, Sarojini K.V.L and Janmenjoy Midya for
their suggestions and assistance in animal handling, and Pradyot
Bhattacharya for providing the human blood samples.
Author Contributions
Conceived and designed the experiments: AD NA. Performed the
experiments: AD. Analyzed the data: AD NA. Contributed reagents/
materials/analysis tools: AD. Wrote the paper: AD NA.
References
1. Alvar J, Ve´lez ID, Bern C, Herrero M, Desjeux P et al. (2012) Leishmaniasis
worldwide and global estimates of its incidence. PLoS One 7:e35671. DOI:
10.1371/journal.pone.0035671.
2. Evans KJ, Kedzierski L. (2012) Development of Vaccines against Visceral
Leishmaniasis. J Trop Med 2012:892817. DOI: 10.1155/2012/892817.
3. Black M, Trent A, Tirrell M, Olive C. (2010) Advances in the design and
delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.
Expert Rev Vaccines 9:157–173.
4. Latif N and Bachhawat BK. (1984) The effect of surface charges of liposomes in
immunopotentiation. Biosci Rep 4:99–107.
5. Korsholm KS, Andersen P, Agger EM. (2011) Cationic liposomes as vaccine
adjuvants. Expert Rev Vaccines 10:513–521.
6. Casella CR and Mitchell TC. (2008) Putting endotoxin to work for us:
monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life
Sci 65:3231–3240.
7. Ryll R, Kumazawa Y, Yano I. (2001) Immunological properties of trehalose
dimycolate (cord factor) and other mycolic acid-containing glycolipids–a review.
Microbiol Immunol 45:801–811.
8. Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, et al. (2009)
MARCO, TLR2, and CD14 are required for macrophage cytokine responses to
mycobacterial trehalosedimycolate and Mycobacterium tuberculosis. PLoS
Pathog 5:e1000474. doi: 10.1371/journal.ppat.1000474.
9. Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K et al.
(2010). Cutting edge: Mincle is essential for recognition and adjuvanticity of the
mycobacterial cord factor and its synthetic analog trehalose-dibehenate.
J Immunol 184:2756–2760.
10. Ravindran R, Bhowmick S, Das A, Ali N. (2010) Comparison of BCG, MPL and
cationic liposome adjuvant systems in leishmanial antigen vaccine formulations
against murine visceral leishmaniasis. BMC Microbiol 10:181. doi: 10.1186/
1471-2180-10-181.
11. Mazumder S, Maji M, Ali N. (2011) Potentiating effects of MPL on DSPC
bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high
immunogenicity and protection. PLoS Negl Trop Dis 5:e1429. DOI: 10.1371/
journal.pntd.0001429.
12. Das A and Ali N. (2012) Vaccine Development Against Leishmania donovani.
Front Immunol. DOI: 10.3389/fimmu.2012.00099.
13. Silva-Almeida M, Pereira BA, Ribeiro-Guimara˜es ML, Alves CR. (2012)
Proteinases as virulence factors in Leishmania spp. infection in mammals. Parasit
Vectors 5:160. DOI: 10.1186/1756-3305-5-160.
14. Mottram JC, Coombs GH, Alexander J. (2004) Cysteine peptidases as virulence
factors of Leishmania. Curr Opin Microbiol 7:375–381.
15. Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH et al. (2004)
Immunization with the hybrid protein vaccine, consisting of Leishmania major
cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against
leishmaniasis. Vaccine 22:1930–1940.
16. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, et al.
(2011) Delivery of a cocktail DNA vaccine encoding cysteine proteinases
type I, II and III with solid lipid nanoparticles potentiate protective
immunity against Leishmania major infection. J Control Release 153:154–
162.
17. Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, et al. (2008)
Cysteine proteinase type III is protective against Leishmania infantum infection
in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Vaccine 26:5822–9.
18. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, et al. (2005). Protective
vaccination against experimental canine visceral leishmaniasis using a combi-
nation of DNA and protein immunization with cysteine proteinases type I and II
of L. infantum. Vaccine 23:3716–25.
19. Melby PC, Chandrasekar B, Zhao W, Coe JE.(2001)The hamster as a model of
human visceral leishmaniasis: progressive disease and impaired generation of
nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol
166:1912–1920.
20. Afrin F, Ali N. (1997) Adjuvanticity and protective immunity elicited by
Leishmania donovani antigens encapsulated in positively charged liposomes.
Infect Immun 65:2371–2377.
21. Tao H, Liu W, Simmons BN, Harris HK, Cox TC, Massiah MA. (2010)
Purifying natively folded proteins from inclusion bodies using sarkosyl, Triton X-
100, and CHAPS. Biotechniques 48:61–64.
22. Zimmerman T, Petit Fre`re C, Satzger M, Raba M, Weisbach M, et al. (2006)
Simultaneous metal chelate affinity purification and endotoxin clearance of
recombinant antibody fragments. J Immunol Methods 314:67–73.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951) Protein measurement
with the Folin phenol reagent. J Biol Chem 193: 265–276.
24. Thompson JD, Higgins DG, Gibson TJ. (1994) CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic
Acids Res 22:4673–80.
25. Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227: 680–685.
26. Bhowmick S, Ravindran R, Ali N. (2008) gp63 in stable cationic liposomes
confers sustained vaccine immunity to susceptible BALB/c mice infected with
Leishmania donovani. Infect Immun 76: 1003–1015.
27. Homhuan A, Harashima H, Yano I. (2008) Cellular attachment and
internalization of cationic liposomes containing mycobacterial cell wall.
ScienceAsia 34: 179–185.
28. Fujiwara T, Akita H, Harashima H. (2010) Intracellular fate of octaarginine-
modified liposomes in polarized MDCK cells. Int J Pharm 386:122–130.
29. Wang M, Zhang Y, Feng J, Gu T, Dong Q, et al. (2013) Preparation,
characterization, and in vitro and in vivo investigation of chitosan-coated poly
(d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
Int J Nanomedicine 8:1141–1154.
30. Kar S, Sharma G, Das PK. (2011) Fucoidan cures infection with both antimony-
susceptible and -resistant strains of Leishmania donovani through Th1 response
and macrophage-derived oxidants. J Antimicrob Chemother 66:618–25.
31. Mazumdar T, Anam K, Ali N. (2004) A mixed Th1/Th2 response elicited by a
liposomal formulation of Leishmania vaccine instructs Th1 responses and
resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22:
1162–1171.
32. Lyons AB. (2000) Analysing cell division in vivo and in vitro using flow
cytometric measurement of CFSE dye dilution. J Immunol Methods 243: 147–
154.
33. Gupta R, Kushawaha PK, Samant M, Jaiswal AK, Baharia RK, et al. (2012)
Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis
of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite
production and antibody responses. J Antimicrob Chemother 67:440–443.
34. Rama In˜iguez S, Dea-Ayuela MA, Sanchez-Brunete JA, Torrado JJ, Alunda JM,
et al. (2006) Real-time reverse transcription-PCR quantification of cytokine
mRNA expression in golden Syrian hamster infected with Leishmania infantum
and treated with a new amphotericin B formulation. Antimicrob Agents
Chemother 50:1195–1201.
35. Lafuse WP, Story R, Mahylis J, Gupta G, Varikuti S et al. (2013). Leishmania
donovani infection induces anemia in hamsters by differentially altering
erythropoiesis in bone marrow and spleen. PLoS One 8:e59509. DOI:
10.1371/journal.pone.0059509.
36. Livak KJ, Schmittgen TD. (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(2Delta Delta C(T)) Method. Methods
25:402–408.
37. Stauber LA, Franchino EM, Grun J. (1958) An eight day method for screening
compounds against Leishmania donovani in the golden hamster. J Protozool
5:269–273.
38. Titus RG, Marchand M, Boon T, Louis JA. (1985) A limiting dilution assay for
quantifying Leishmania major in tissues of infected mice. Parasite Immunol
7:545–555.
39. Nair S, Buiting AM, Rouse RJ, Van Rooijen N, Huang L, et al. (1995) Role of
macrophages and dendritic cells in primary cytotoxic T lymphocyte responses.
Int Immunol 7:679–688.
40. Fortin A, Lagace´ J, The´rien HM. (2001) Trafficking of surface-linked and
encapsulated liposomal antigens in macrophages: an immunocytochemical
study. J Histochem Cytochem 49:1407–1420.
41. Harding CV, Collins DS, Slot JW, Geuze HJ, Unanue ER. (1991) Liposome-
encapsulated antigens are processed in lysosomes, recycled, and presented to T
cells. Cell 64:393–401.
42. Dal Monte P, Szoka FC Jr.(1989) Effect of liposome encapsulation on antigen
presentation in vitro. Comparison of presentation by peritoneal macrophages
and B cell tumors. J Immunol 142:1437–143.
43. Szoka FC Jr. (1992) The macrophage as the principal antigen-presenting cell for
liposome-encapsulated antigen. Res Immunol 143:186–188.
Cocktail Vaccination against Leishmania donovani
PLOS Neglected Tropical Diseases | www.plosntds.org 16 August 2014 | Volume 8 | Issue 8 | e3091
44. Su D, Van Rooijen N. (1989) The role of macrophages in the immunoadjuvant
action of liposomes: effects of elimination of splenic macrophages on the immune
response against intravenously injected liposome-associated albumin antigen.
Immunology 66: 466–470.
45. McConville MJ, Naderer T. (2011) Metabolic pathways required for the
intracellular survival of Leishmania. Annu Rev Microbiol 65:543–61.
46. Saha DC, Astiz ME, Lin RY, Rackow EC, Eales LJ. (1997) Monophosphoryl
lipid A stimulated up-regulation of nitric oxide synthase and nitric oxide release
by human monocytes in vitro. Immunopharmacology 37:175–184.
47. Saha DC, Barua RS, Astiz ME, Rackow EC, Eales-Reynolds LJ. (2001)
Monophosphoryl lipid A stimulated up-regulation of reactive oxygen interme-
diates in human monocytes in vitro. J Leukoc Biol 70:381–385.
48. Coffman R L, Lebman DA, Rothman P. (1993) Mechanism and regulation of
immunoglobulin isotype switching. Adv Immunol 54: 229–270.
49. Rodrigues Junior V, Da Silva JS, Campos-Neto A. (1992) Selective inability of
spleen antigen presenting cells from Leishmania donovani infected hamsters to
mediate specific T cell proliferation to parasite antigens. Parasite Immunol 14:
49–58.
50. Gautam S, Kumar R, Singh N, Singh AK, Rai M, et al. (2013) CD8 T Cell
Exhaustion in Human Visceral Leishmaniasis. J Infect Dis. doi: 10.1093/infdis/
jit401.
51. Phillips R, Svensson M, Aziz N, Maroof A, Brown N, et al. (2010) Innate killing
of Leishmania donovani by macrophages of the splenic marginal zone requires
IRF-7. PLoS Pathog 6(3):e1000813. DOI: 10.1371/journal.ppat.1000813.
52. Nieto A, Domı´nguez-Bernal G, Orden JA, De La Fuente R, Madrid-Elena N,
Carrio´n J. (2011) Mechanisms of resistance and susceptibility to experimental
visceral leishmaniosis: BALB/c mouse versus syrian hamster model. Vet Res
42:39.
53. Giudice A, Vendrame C, Bezerra C, Carvalho LP, Delavechia T, et al. (2012).
Macrophages participate in host protection and the disease pathology associated
with Leishmania braziliensis infection. BMC Infect Dis 12:75.
54. Murray HW. (2001) Tissue granuloma structure-function in experimental
visceral leishmaniasis. Int J Exp Pathol 82: 249–267.
55. Stanley AC, Engwerda CR. (2007) Balancing immunity and pathology in
visceral leishmaniasis. Immunol Cell Biol 85:138–147.
56. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell J.P. (2001) IL-10
mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31:
2848–2856.
57. Banerjee R, Kumar S, Sen A, Mookerjee A, Mukherjee P, et al. (2011) TGF-b-
regulated tyrosine phosphatases induce lymphocyte apoptosis in Leishmania
donovani-infected hamsters. Immunol Cell Biol 89:466–474.
58. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. (2005)
Trends Parasitol 21:244–249.
59. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K et al. (2002).
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial
vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20:292–303.
60. Azmi F, Ahmad Fuaad AA, Skwarczynski M, Toth I. (2013) Recent progress in
adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immun-
other 10:778 – 796.
61. Birnbaum R, Craft N. (2011). Innate immunity and Leishmania vaccination
strategies. Dermatol Clin 29:89–102.
62. Kumar R and Engwerda C. (2014). Vaccines to prevent leishmaniasis. Clinical
& Translational Immunology. 3, e13; doi:10.1038/cti.2014.4.
63. Edin J . Mifsud, Amabel CL . Tan, David C . Jackson. (2014) TLR Agonists as
Modulators of the Innate Immune Response and Their Potential as Agents
against Infectious Disease. Front Immunol 5: 79.
64. Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA. (2011) Co-encapsulation
of antigen and Toll-like receptor ligand in cationic liposomes affects the quality
of the immune response in mice after intradermal vaccination. Vaccine
29:1045–1052.
65. Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. (2007) ‘‘Pathogen-
mimicking’’ nanoparticles for vaccine delivery to dendritic cells. J Immunother
30:378–395.
66. Garg R, Dube A. (2006) Animal models for vaccine studies for visceral
leishmaniasis. Indian J Med Res 123:439–54.
67. Oussoren C Velinova M, Scherphof G, van der Want JJ, van Rooijen N, Storm
G.(1998) Lymphatic uptake and biodistribution of liposomes after subcutaneous
injection. IV. Fate of liposomes in regional lymph nodes. Biochim Biophys Acta
1370:259–272.
68. Peyre M, Fleck R, Hockley D, Gander B, Sesardic D. (2004) In vivo uptake of an
experimental microencapsulated diphtheria vaccine following sub-cutaneous
immunization. Vaccine 22:2430–437.
69. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. (2012)
Enhancing humoral responses to a malaria antigen with nanoparticle vaccines
that expand Th cells and promote germinal center induction. Proc Natl Acad
Sci U S A 109:1080–1085.
70. Stober CB, Lange UG, Roberts MT, Alcami A and Blackwell JM. (2005) IL-10
from regulatory T cells determines vaccine efficacy in murine Leishmania major
infection. J Immunol 175: 2517–2524.
71. Bacellar O, D’Oliveira A, Jeroˆnimo Jr S, Carvalho EM. (2000) IL-10 and IL-12
are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12: 1228–
1231.
72. Maynard CL, Weaver CT. (2008) Diversity in the contribution of interleukin-10
to T-cell-mediated immune regulation. Immunol Rev 226:219–33.
73. Bhowmick S, Ali N. (2009) Identification of novel Leishmania donovani antigens
that help define correlates of vaccine-mediated protection in visceral
leishmaniasis. PLoS One 4(6):e5820.
74. Rao M, Bray M, Alving CR, Jahrling P, Matyas GR. (2002) Induction of
immune responses in mice and monkeys to Ebola virus after immunization with
liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4
(+) T cells. J Virol 76:9176–85.
75. Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W et al. (1996) Safety,
immunogenicity, and efficacy of Plasmodium falciparum repeatless circumspor-
ozoite protein vaccine encapsulated in liposomes. J Infect Dis 174:361–366.
76. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The
vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
Science 316:1628–32.
77. Seder RA, Hill AV. (2000) Vaccines against intracellular infections requiring
cellular immunity. Nature 406:793–798.
78. Evans K.J., Kedzierski L. (2012) Development of Vaccines against Visceral
Leishmaniasis. J Trop Med. DOI: 10.1155/2012/892817.
79. Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R et al. (2011) KSAC, the
first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin
Vaccine Immunol 18:1118–124.
80. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. (2007) Leish-111f, a
recombinant polyprotein vaccine that protects against visceral Leishmaniasis by
elicitation of CD4+ T cells. Infect Immun 75:4648–654.
81. Gurunathan S, Prussin C, Sacks DL, Seder RA. (1998) Vaccine requirements for
sustained cellular immunity to an intracellular parasitic infection. Nat Med 4:
1409–1415.
82. Tewary P, Saxena S, Madhubala R. (2006) Co-administration of IL-12 DNA
with rORFF antigen confers long-term protective immunity against experimen-
tal visceral leishmaniaisis. Vaccine 24: 2409–2416.
83. Stager S, Smith DF, Kaye PM. (2000) Immunization with a recombinant stage-
regulated surface protein from Leishmania donovani induces protection against
visceral leishmaniasis. J Immunol 165: 7064–7071.
84. Bhowmick S, Mazumdar T, Sinha R, Ali N. (2010) Comparison of liposome
based antigen delivery systems for protection against Leishmania donovani.
J Controlled Release 141: 199–207.
85. Bhowmick S, Ravindran R, Ali N. (2007) Leishmanial antigens in liposomes
promote protective immunity and provide immunotherapy against visceral
leishmaniasis via polarized Th1 response. Vaccine 25: 6544–6556.
86. Ravindran R, Maji M, Ali N. (2012) Vaccination with liposomal leishmanial
antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate
(MPL-TDM) confers long-term protection against visceral leishmaniasis through
a human administrable route. Mol Pharm 9:59–70.
Cocktail Vaccination against Leishmania donovani
PLOS Neglected Tropical Diseases | www.plosntds.org 17 August 2014 | Volume 8 | Issue 8 | e3091
